<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631512</url>
  </required_header>
  <id_info>
    <org_study_id>WBG-03</org_study_id>
    <nct_id>NCT02631512</nct_id>
  </id_info>
  <brief_title>Evaluation of Woulgan in Diabetic Foot Ulcer</brief_title>
  <official_title>Evaluation of Woulgan in Diabetic Foot Ulcer Compared With a Commercial Hydrogel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotec Pharmacon ASA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotec Pharmacon ASA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to support the performance and safety of Woulgan® in the
      treatment of diabetic foot ulcer in comparison with the commercially available hydrogel
      Intrasite. Healing and untoward medical events to be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of Woulgan Gel as primary dressing in diabetic foot ulcer in terms of reduced wound size in sqcm.</measure>
    <time_frame>Until 8 weeks from start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of Woulgan Gel as primary dressing in diabetic foot ulcer measured in terms of untoward medical events</measure>
    <time_frame>Until 8 weeks from start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Useability of Woulgan as primary dressing in diabetic foot ulcer measured as degree of pain (100 mm VAS).</measure>
    <time_frame>Until 8 weeks from start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetic Foot Ulcers</condition>
  <arm_group>
    <arm_group_label>Woulgan Gel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Primary dressing with Woulgan Gel with Soluble Beta-Glucan (SBG)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intrasite Hydrogel</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Primary dressing with Intrasite Hydrogel</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Woulgan Gel</intervention_name>
    <description>Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.</description>
    <arm_group_label>Woulgan Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intrasite Hydrogel</intervention_name>
    <description>Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage</description>
    <arm_group_label>Intrasite Hydrogel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type I or II diabetes mellitus.

          -  Target ulcer area between 0.5 and 5 sqcm, and more than 4 weeks old.

          -  Ankle-brachial pressure index above 0.7.

        Exclusion Criteria:

          -  Ulcers due to non-diabetic etiology.

          -  Uncontrolled diabetes defined as HbA1c above 70 mmol/mol and insufficient nutritional
             status.

          -  Ulcers older than 1 year.

          -  Any of gangrene, osteomyelitis, cellulitis, or Charcot osteoarthropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magnus Londahl, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rolf E Engstad, PhD</last_name>
    <phone>+4777648900</phone>
    <email>rolf.engstad@biotec.no</email>
  </overall_contact>
  <location>
    <facility>
      <name>Skaane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>S-22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Löndahl, MD PhD</last_name>
      <email>magnus.londahl@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Middlesex University Hospital</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hilary Tindall, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG72UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Jeffcoate, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

